Abbreviations. DMEM/FBS, Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum; ERK1/2, extracellular signal-regulated kinases 1/2; pERK1/2, phosphorylated ERK1/2; HRP, horseradish peroxidase; MBP, myelin basic protein; MEK1/2, mitogen-activated protein kinases 1 and 2; pMEK1/2, phosphorylated MEK1/2; MMP-2, matrix metalloproteinase-2; MT1-MMP, membrane type-1 matrix metalloproteinase; MT1-CAT, the individual catalytic domain of MT1-MMP; p90RSK, 90 kDa ribosomal S6 kinase; p-p90RSK, phosphorylated p90RSK; PDX, α 1 -antitrypsin Portland; PEX, hemopexin domain; proMMP-2, the latent proenzyme of MMP-2; TIMP-2, tissue inhibitor of metalloproteinases-2.
3 control. [5] [6] [7] MT1-MMP is directly involved in the pericellular proteolysis of the matrix, in the activation of soluble MMPs, and in the cleavage of the cell receptors. 3 The presence of the transmembrane and the cytoplasmic domains distinguishes MT1-MMP from the soluble MMPs.
The MT1-MMP zymogen also exhibits an N-terminal prodomain, a catalytic domain, a hinge and a C-terminal hemopexin (PEX) domain. To become active, the MT1-MMP zymogen requires proteolytic activation. 8, 9 The N-terminal prodomain is removed by furin during the secretion pathway of MT1-MMP and the catalytic site of the emerging MT1-MMP enzyme becomes liberated.
The catalytic domain of MT1-MMP binds TIMP-2 with high affinity. 10 TIMP-2 is a member of a multigene family (TIMP-1 through -4) that binds non-covalently to active MMPs in a 1:1 molar ratio and inhibits their activity. 11 In contrast with TIMP-2, TIMP-1 does not inhibit MT1-MMP. 10 MMP/TIMP balance, including the balance of MT1-MMP with TIMP-2, is a major factor in the regulation of the proteolytic activity of MMPs. 1 
TIMP-2 contains two domains. The inhibitory N-terminal domain binds the active site of
MMPs including MT1-MMP, blocking the access of substrates to the catalytic site. 12 The Cterminal domain of TIMP-2 binds to the PEX domain of proMMP-2. 13, 14 This binding mode is essential for the cell surface activation of proMMP-2 by MT1-MMP. 4, 15 The peptide sequence of the PEX domain is conserved in the MMP family. This domain regulates the interactions of MT1-MMP with its cleavage targets including CD44 and the α integrins. [16] [17] [18] The PEX is also responsible for the formation of the MT1-MMP homodimers, the presence of which is essential for the activation of MMP-2. 19 Our earlier data suggest that MT1-MMP's PEX binds the C-terminal domain of TIMP-2 in a manner similar to proMMP-2. It is likely that these interactions, rather than binding the N-4 terminal domain of TIMP-2 with the catalytic domain of MT1-MMP, are required for the induction of the Ras/Raf/ERK signaling cascade. 20 The stimulation of this cascade appears to play a significant role in the functionality of MT1-MMP. Because in our earlier work we used transfected cells, which overexpressed MT1-MMP, we limited the significance of our findings.
To extend our results, we now show that TIMP-2 binding to MT1-MMP, which is naturally expressed by cancer cells, activates the intracellular cascade that involves MEK1/2, ERK1/2 and the downstream ERK substrate p90RSK. We show that the MT1-MMP/TIMP-2 complex stimulates cell locomotion via a mechanism that is independent of and in addition to the proteolytic activity of MT1-MMP.
21, 22

Material and Methods
Reagents -Unless otherwise indicated, reagents were purchased from Sigma (St. Louis, MO).
Human 18.5 kDa myelin basic protein (MBP) was from Biodesign International (Saco, ME). The individual catalytic domain of MT1-MMP (MT1-CAT) was purified from the E. coli inclusion bodies and refolded to restore its catalytic activity. 23 Human TIMP-1, a rabbit anti-human antibody to the hinge (AB815) and a murine monoclonal antibody against the catalytic domain of MT1-MMP (3G4), a TMB/M substrate and a hydroxamate inhibitor (GM6001) were from Chemicon (Temecula, CA). The goat anti-human TIMP-2 antibody (AF971) was from R&D µg/ml streptomycin. Cells were electroporated with the human TIMP-2 cDNA in the bi-cistronic adenoviral vector that encoded methotrexate-resistant DHFR. 24 Stable transfectants were selected using α-MEM supplemented with 500 nM methotrexate. To amplify the DHFR-TIMP-2 gene number, the methotrexate levels in the medium were doubled each week to reach a 25 µM final concentration. TIMP-2 was purified from the 5-day culture medium (500 ml). The medium was concentrated 10-fold using a 400 ml ultrafiltration cell with a 10 kDa cut-off membrane (HT-neo cells) were obtained and characterized earlier. 25 Human glioma U251 cells (U-MT/PDX cells) co-transfected with both MT1-MMP and PDX were isolated and characterized earlier. 26, 27 Cells were cultured in DMEM/FBS and 10 µg/ml gentamicin.
siRNA constructs -Selection of the siRNA and siRNAscr constructs was based on our previous extensive investigations. 25 , 27, 28 We tested the transcription silencing efficiency of six MT1-MMP siRNA constructs (numbered 1 through 6) designed using the siRNA Designer software (www.promega.com/techserv/siRNADesigner). As controls, we evaluated several scrambled 6 constructs (Supplemental Table 1 ). The sequence of construct 1 was identical with that of MT1-MMP siRNA reported earlier. 29 The efficiency of MT1-MMP silencing was determined using FACS, immunoblotting and gelatin zymography. The siRNA construct 3 was the most efficient in silencing MT1-MMP. HT1080 cells in which MT1-MMP transcription was silenced (MT1-MMP-siRNA cells) using the construct 3 and a scrambled siRNA-transfected cell control (siRNAscr cells) were isolated earlier. 25 No off-target effects of the constructs were observed. To avoid clone-specific effects, transfected cell lines were generated as pools of 3-6 positive cell clones. Transfected cells were grown in the presence of 1 µg/ml puromycin. Gelatin zymography -Gelatin zymography of the serum-free medium samples was performed as described previously. 28, 30 Where indicated, TIMP-2 (10-1000 ng/ml) and GM6001 (10 µM) alone or in combination were added to the cells.
Cell surface biotinylation -
Immunoblotting -Cells were grown in DMEM/FBS for 18 h. The medium was replaced with DMEM containing TIMP-2 (10-1000 ng/ml), GM6001 (10 µM) and U0126 (10 µM) alone or in 
Results
Transcriptional silencing of MT1-MMP in HT1080 cells -
The results we describe here represent the continuations of our published study in which we have used breast carcinoma MCF-7 cells which were stably transfected and, as a result, overexpressed MT1-MMP. 20 We now specifically selected HT1080 cells because they express MT1-MMP naturally. To silence MT1-MMP, we stably transfected HT1080 cells with the siRNA construct and isolated MT1-MMP-siRNA cells.
As a control, we isolated siRNAscr cells, which were transfected with the scrambled construct (Supplemental Table 1 ).
By using an immunoblotting analysis of the cell lysates we confirmed the near complete repression of MT1-MMP in MT1-MMP-siRNA cells. In turn, the scrambled siRNA construct did not exhibit any significant effect on MT1-MMP ( lysed. An immunoblotting analysis determined the levels of both ERK1/2 phosphorylation and total ERK1/2 in the lysates (Fig. 2) . As a control, we determined the levels of pSrc and total Src.
TIMP-2 induced a significant level of ERK1/2 phosphorylation in siRNAscr cells. GM6001 did not reverse the stimulatory effect of TIMP-2 on phosphorylation of ERK1/2 in siRNAscr cells.
As we expected, 20 TIMP-2 did not induce any significant activation of ERK1/2 in MT1-MMPsiRNA cells. In contrast with pERK1/2, TIMP-2 did not affect the levels of both pSrc and total Src in both MT1-MMP-siRNA and siRNAscr cells, thus supporting the specific activation of the ERK pathway.
TIMP-2 used in these tests was highly purified. Its purity was confirmed by both gel electrophoresis and immunoblotting. TIMP-2, at the molar ratio of MT1-CAT -TIMP-2 equal to 1:2, completely blocked the cleavage of MBP (a sensitive protein substrate of MT1-MMP) by MT1-CAT, thus indicating the high inhibitory potency of our TIMP-2. TIMP-2 (100 ng/ml) blocked the activation of MMP-2 in HT1080 cells (Supplemental Fig. 1 ). These tests confirmed the inhibitory efficiency of TIMP-2 and suggested that TIMP-2 itself caused ERK1/2 activation in siRNAscr cells. Fig. 3) . In parallel, we co-incubated the cells for 24 h with the same concentrations of TIMP-2. The concentrations of TIMP-2 we used are comparable with those of endogenous TIMP-2 measured using ELISA in the medium conditioned for 24 h by HT1080 cells (1x10 6 /ml). 34 We then determined the levels of pERK1/2 and total ERK1/2, and pSrc and total Src in the cells using immunoblotting analyses. We also examined the levels of active MT1-MMP by In contrast to MT1-MMP-siRNA cells, there was an obvious effect of TIMP-2 on the levels of MMP-2 activation, pERK1/2 and the migration efficiency in siRNAscr cells. The noticeable level of the activation of MMP-2 was observed at 10-50 ng/ml TIMP-2, while a further increase in TIMP-2 levels inhibited MMP-2 activation by siRNAscr cells. In turn, both the efficiency of migration and the phosphorylation of ERK1/2 were at their highest levels at 50 ng/ml TIMP-2. Over 100 ng/ml TIMP-2 repressed the levels of MMP-2 activation and the migration efficiency but maintained the pERK1/2 levels in siRNAscr cells.
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In contrast to pERK1/2, TIMP-2 did not significantly affect total ERK1/2, pSrc and total Src in siRNAscr cells, although some minor variations in the low levels of pSrc and total Src were observed (Fig. 3) . A quantitative densitometry analysis did not reveal any significant TIMP-2-induced changes in the pSrc-total Src ratio in MT1-MMP-siRNA and siRNAscr cells (Fig. 3) . Incubation for 24 h with GM6001 alone or in combination with TIMP-2 had no effect on the levels of pSrc and total Src in MT1-MMP-siRNA and siRNAscr cells (Supplemental Fig.   2 ).
These results suggest that the migration efficiency of siRNAscr cells is controlled by the proteolytic and the non-proteolytic mechanisms, both of which employ TIMP-2 as a mediator. In the non-proteolytic mechanism, stimulation of ERK1/2 phosphorylation requires lower concentrations of TIMP-2 compared to those which are required for the quantitative inhibition of the proteolytic activity of MT1-MMP.
TIMP-2 stimulated phosphorylation of MEK1/2 -To corroborate our results, we tested if
MEK1/2, which is directly upstream of ERK1/2, is activated by TIMP-2. For this purpose, we co-incubated cells for 24 h with TIMP-2 (50 ng/ml and 100 ng/ml), GM6001 and U0126 alone and in combination (Fig. 4) . We then used immunoblotting to measure the levels of MEK and ERK in cell lysates. No significant effect of TIMP-2, GM6001 and U0126 was observed in MT1-MMP-siRNA cells. In contrast, a significant effect was evident in siRNAscr cells. TIMP-2 strongly increased the levels of both pMEK1/2 and pERK1/2 in siRNAscr cells. U0126 reversed the stimulatory effect of TIMP-2 on pMEK1/2 and pERK1/2 while GM6001 alone or in combination with 100 ng/ml TIMP-2 had no significant effect on MEK and ERK (Fig. 4) .
Similar effects were observed with 50 ng/ml TIMP-2 ( Fig. 4 and Supplemental Fig. 3 ).
These data demonstrated that the low, 50 ng/ml and 100 ng/ml, concentrations of TIMP-2 were To investigate the effect of GM6001, we measured the efficiency of migration of cells in the presence of 50 ng/ml TIMP-2 and GM6001 alone and in combination (Fig. 4) . In siRNAscr cells, TIMP-2 (50 ng/ml) and GM6001 increased and inhibited migration, respectively. TIMP-2 and GM6001 had no significant effect in MT1-MMP-siRNA cells. If the inhibitors were used jointly, GM6001 had only a minor effect on the TIMP-2-induced migration stimulation in siRNAscr cells. (100 ng/ml) alone and in combination with GM6001. The levels of p-p90RSK were estimated using immunoblotting of the cell lysates. We also used gelatin zymography to determine the ability of cellular MT1-MMP to activate MMP-2. Our results showed that both TIMP-2 and GM6001 were without effect in MT1-MMP-siRNA cells (Fig. 5) . As expected, GM6001 alone inhibited MT1-MMP and this event resulted in the detection of only proMMP-2 in the siRNAscr medium. GM6001 did not increase the level of pMEK1/2 in siRNAscr cells when compared with the untreated control. Compared to GM6001, TIMP-2 (100 ng/ml) was less efficient in inhibiting MMP-2 activation in siRNAscr cells. In contrast with GM6001, TIMP-2 up-regulated the levels of both pMEK1/2 and p-p90RSK in siRNAscr cells (Fig. 5) . (Fig 6) . These results were consistent with earlier observations. 20, 30, 37, 38 TIMP-2 induced MEK1/2 activation in HT1080 cells but not in MCF-7 cells (Fig. 6 ).
TIMP-2 stimulated phosphorylation of p90RSK -
Discussion
Discussion Discussion Discussion
High levels of TIMP-2 positively correlate with an unfavorable prognosis in cancer patients. [39] [40] [41] [42] [43] [44] There are additional reports that both aberrant hypermethylation of the TIMP-2 The concentrations of TIMP-2 in tissues and biological fluids are in the 10-220 ng/ml range. [52] [53] [54] [55] [56] The concentrations of endogenous TIMP-2 in the medium conditioned by HT1080 cells are also close to 100 ng/ml. 34 Previous studies by others employed TIMP-2 concentrations which were 10-to 500-fold higher when compared with the physiological range. 6, 7, [31] [32] [33] The physiological concentrations of TIMP-2 we used stimulated ERK signaling in HT1080 cells. We 
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